Oblique Therapeutics
  • Home Page
  • About us
    • Overview
    • Organization
  • Technology
    • AbiprotTM-antibody platform
    • Abiprot SelectTM
  • Portfolio
    • Overview
    • OT-1096 in TNBC
    • aTRPV1 & aTRPA1 in pain
    • aKRAS in colorectal cancer
    • Collaborations in type 2 diabetes
  • Corporate Gouvernance
    • General annual meetings
    • Board of Directors and Management
  • Investors Relations
    • Reports
  • News
    • Press Releases
    • Publications, conferences & press
  • Contact
Oblique Therapeutics > News
  • Home Page
  • About us
    • Overview
    • Organization
  • Technology
    • AbiprotTM-antibody platform
    • Abiprot SelectTM
  • Portfolio
    • Overview
    • OT-1096 in TNBC
    • aTRPV1 & aTRPA1 in pain
    • aKRAS in colorectal cancer
    • Collaborations in type 2 diabetes
  • Corporate Gouvernance
    • General annual meetings
    • Board of Directors and Management
  • Investors Relations
    • Reports
  • News
    • Press Releases
    • Publications, conferences & press
  • Contact

News

Archive
  • November 2020
  • October 2020
  • September 2020
  • June 2020
  • November 2019
  • October 2019
  • July 2019
  • March 2019
  • January 2019
  • November 2018
  • October 2018
  • September 2018
Categories
  • Company updates
  • News
27 Nov 2019

Notice convening the Extraordinary General Meeting on December 6 at 2pm

24 Oct 2019

Oblique will be presenting at the RAS-Targeted Drug Discovery Europe Summit in February

10 Oct 2019

Oblique Therapeutics is on EU-Startups top 10 list -“10 European biotech startups to look out for in 2019 and beyond”

17 Jul 2019

We are proud to have been recognised by StartUp City Magazine as one of the most promising European Biotech startups in 2019!

28 Mar 2019

We welcome our new owners

07 Mar 2019

New collaboration with Pharma

10 Jan 2019

Oblique Therapeutics at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco

01 Nov 2018

BioEurope

  • «
  • 1
  • 2
  • 3
  • 4
  • »
Archive
  • November 2020
  • October 2020
  • September 2020
  • June 2020
  • November 2019
  • October 2019
  • July 2019
  • March 2019
  • January 2019
  • November 2018
  • October 2018
  • September 2018
Categories
  • Company updates
  • News
Oblique Therapeutics

Copyright © 2021 Oblique Therapeutics AB.

Contact

Oblique Therapeutics AB
info@obliquet.com

Gothenburg
Arvid Wallgrens Backe 20
413 46 Göteborg
Sweden

Stockholm
Döbelnsgatan 64
113 52 Stockholm
Sweden

Menu
  • Home Page
  • About us
    • Overview
    • Organization
  • Technology
    • AbiprotTM-antibody platform
    • Abiprot SelectTM
  • Portfolio
    • Overview
    • OT-1096 in TNBC
    • aTRPV1 & aTRPA1 in pain
    • aKRAS in colorectal cancer
    • Collaborations in type 2 diabetes
  • Corporate Gouvernance
    • General annual meetings
    • Board of Directors and Management
  • Investors Relations
    • Reports
  • News
    • Press Releases
    • Publications, conferences & press
  • Contact
About

Oblique Therapeutics is a privately held Swedish biotech developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and advanced cancer.  The company uses AbiprotTM, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. 

Till toppen

We use cookies to improve the user experience on Oblique Therapeutics. Read more about Cookies

Approve